Could a second shot keep RSV at bay for seniors?
NCT ID NCT07117487
Summary
This study is testing a new RSV vaccine booster shot from Moderna. It's for adults aged 60 and older who received an RSV vaccine (Arexvy or Abrysvo) at least a year ago. The main goals are to see how safe the booster is and how well it strengthens the body's defenses against RSV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indago Research & Health Center, Inc.
Hialeah, Florida, 33012, United States
-
Velocity Clinical Research, Austin
Austin, Texas, 78759, United States
-
Velocity Clinical Research, Covington
Covington, Louisiana, 70433, United States
-
Velocity Clinical Research, Denver
Denver, Colorado, 80110, United States
-
Velocity Clinical Research, Hampton
Hampton, Virginia, 23666, United States
-
Velocity Clinical Research, Lincoln
Lincoln, Nebraska, 68510, United States
-
Velocity Clinical Research, Medford
Medford, Oregon, 97504, United States
-
Velocity Clinical Research, Rockville
Rockville, Maryland, 20854, United States
-
Velocity Clinical Research, Savannah
Savannah, Georgia, 31406, United States
-
Velocity Clinical Research, Spokane
Spokane, Washington, 99218, United States
-
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, 46383, United States
Conditions
Explore the condition pages connected to this study.